CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ApicHope Pharmaceutical Group Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ApicHope Pharmaceutical Group Co Ltd
17-19F, Yunrun Mansion, No.27 Huanyu 1st
Guangzhou International Biological Islan
Phone: +86 2028877623p:+86 2028877623 GUANGZHOU, GNG  510320  China Ticker: 300723300723
Business Summary
ApicHope Pharmaceutical Group Co Ltd, formerly ApicHope Pharmaceutical Co Ltd, is a China-based company primarily engaged in the research and development, production and sales of pharmaceuticals. The Company mainly focuses on the fields of pediatrics drug and chronic disease drug, and its product categories cover chemical medicine (including raw materials and preparations), special Chinese patent medicine, biological vaccines and other fields. The Company’s paediatric drugs are used to treat common diseases, such as children's influenza, colds, infectious diseases, functional dyspepsia and others. The Company’s chronic disease drugs are used for treatment of cardiovascular and cerebrovascular diseases, kidney diseases, digestive system diseases, liver diseases and other diseases. The Company’s main products include Fuganlin oral liquid, clindamycin hydrochloride palmitate dispersible tablets and other products. The Company mainly conducts its business in the domestic market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager HanxiongLi 50 9/6/2022 11/27/2018
Chief Financial Officer HuixingZhang 58 12/7/2021 12/7/2021
Deputy General Manager, Secretary of the Board MingyuanZhang 39 7/18/2024 9/6/2022
4 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,676 (As of 12/31/2023)
Outstanding Shares: 454,143,281 (As of 9/30/2024)
Shareholders: 10,013
Stock Exchange: SHE
Fax Number: +86 2028877668


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025